Background Relapsing polychondritis (RP) - is a rare systemic disease with undulating course, presumably autoimmune origin characterized by recurring exacerbations of inflammation in the cartilage tissue, leading to their destruction. Clinical manifestations of RP are divided according to location, severity and duration. In the pathological process may involve all types of cartilage and other structures, rich proteoglycans: eyes, internal ear and vessels. So far, a unified approach to the treatment of RP in terms of evidence-based medicine does not exist. Due to the rarity of the disease clinical studies for comparative evaluation of different drugs have been conducted. For relief of attacks polychondritis most commonly used nonsteroidal antiinflammatory drugs (NSAIDs) and glucocorticoid therapy (corticosteroids), but there is no evidence of their impact on the progression of the process and to prevent relapse.
Objectives to study the efficiency of pulse therapy in patients with RP.
Methods 4 patients with RP were hospitalized in the clinic of I cardiorheumatological department of Tashkent Medical Academy (TMA). The diagnosis was made on the basis of diagnostic criteria developed by Macadam. All patients underwent clinical, immunological, biochemical studies, chest X-ray, ECG.
Results Patients were performed following treatment, Prednisolone 30 mg/day per os, NSAIDs and combination pulse therapy course (1st and 3rd - days solumedrol 1.0 g intravenously, the second day solumedrol 1.0 g in combination with cyclophosphamide 800 mg). The therapy was showed improvement of general condition of patients, decreased pain in the cartilage of nose and swelling of ears, back pain, general weakness. Patients were discharged under the supervision of district therapeutist and rheumatologist with recommendations to continue receiving NSAIDs, corticosteroids and program of the pulse therapy for 6 months.
Conclusions Thus, the use in the treatment of RP pulse therapy had a positive effect on the clinical condition of patients and prevent progression of disease.
Disclosure of Interest None declared